33 results about "Brain-derived neurotrophic factor" patented technology

The invention belongs to the technical field of immunodetection, and discloses a kit for detecting the ratio of proBDNF to maure BDNF based on structural dynamics guidance and a preparation method of the kit, the kit comprises a solid phase carrier and a detection reagent, the three antibodies are determined on the basis of full-length conformational kinetics analysis of brain-derived neurotrophic factors; the first capture antibody targets an innate disorder region (SEQ ID NO: 1) of a proBDNF propeptide region; the second capture antibody targets an innate disorder region (SEQ ID NO: 2) of a proBDNF propeptide region; the second capture antibody is a neo-epitope specific antibody, is specifically combined with an N terminal (SEQ ID NO: 2) exposed by maure BDNF enzyme digestion, and is combined with a free alpha-amino group strictly dependent on the first histidine; and the universal detection antibody is combined to a Loop 4 region (SEQ ID NO: 3) of the Mature structural domain. The problems of steric hindrance and cross reaction in traditional immunodetection are solved through a structural biology strategy, and accurate distinguishing and ratio quantification of proBDNF and maure BDNF are achieved.

The invention relates to application of bifidobacterium animalis subsp. Lactis BLa80 in preparation of a preparation for relieving depression or anxiety. The bifidobacterium animalis subsp. Lactis BLa80 is a strain of the bifidobacterium animalis subsp. Lactis BLa80 with the preservation number of CGMCC (China General Microbiological Culture Collection Center) No.22547, and the strain of the bifidobacterium animalis subsp. Lactis BLa80 is a strain of the bifidobacterium animalis subsp. Lactis BLa80 with the preservation number of CGMCC No.22547. The invention develops a brand new application of the bifidobacterium animalis subsp. Lactis BLa80 strain, namely, the bifidobacterium animalis subsp. Lactis BLa80 strain is used for relieving depression or anxiety symptoms, specifically, the bifidobacterium animalis subsp. Lactis BLa80 strain can stimulate RIN14B cells to secrete 5-HT, can relieve depression and anxiety-like behaviors of mice suffering from depression and anxiety, can relieve hyperfunction of hypothalamic-pituitary-adrenal axis (HPA axis), and can relieve depression and anxiety-like behaviors of mice suffering from depression and anxiety. The inflammatory response of mice with depression and anxiety is relieved, the expression level of brain-derived neurotrophic factors in hippocampus of the mice with depression and anxiety is improved, the abundance of intestinal beneficial flora of the mice with depression and anxiety is improved, and the diversity of intestinal flora is increased.

The present application belongs to the field of functional substance research, and particularly relates to a nutritional composition for promoting brain development and use thereof. The nutritional composition provided by the present application comprises essential active ingredients shown in (i) and (ii) as follows: (i) lysophosphatidylethanolamine; (ii) 3'-SL; wherein the essential active ingredient shown in (i) at least comprises lysophosphatidylethanolamine with a fatty acid chain with a length of 14-22 carbon atoms connected at the sn-1 position, and in the nutritional composition, the mass ratio of the essential active ingredient shown in (i) to the essential active ingredient shown in (ii) is 1:(1-450). The combination of lysophosphatidylethanolamine and breast milk oligosaccharide 3'-SL can effectively promote the overall development of the body, especially the brain development, and improve the relative gene expression amount of brain-derived neurotrophic factor and glial cell-derived neurotrophic factor in brain tissue, thereby effectively assisting the improvement of cognitive ability.

The present application relates to a nutritional composition, a product comprising the same and use thereof in the preparation of a product for alleviating synaptic plasticity impairment of a body. The nutritional composition comprises: docosahexaenoic acid (DHA) and / or a metabolic precursor thereof, sodium hyaluronate (SH), and lactoferrin (LF). When docosahexaenoic acid (DHA), sodium hyaluronate (SH) and lactoferrin (LF) are used in combination, they can synergistically alleviate synaptic plasticity impairment of a body, in particular, increase nerve growth factor (NGF) content and / or brain-derived neurotrophic factor (BDNF) content in PC12 cells of the body, and / or increase expression of synaptic-related proteins in PC12 cells of the body.

The application provides application of an acetyl dopamine compound in preparation of a medicine for improving insomnia, and belongs to the technical field of traditional Chinese medicine medicines, and the acetyl dopamine compound is acetyl dopamine dimer A extracted from cicada slough. Experiments prove that the acetyl dopamine dimer A can increase the content of brain-derived neurotrophic factor (BDNF) which plays an important role in the occurrence process of insomnia, reduce dopamine (DA) level, and has obvious effects on DA metabolites homovanillic acid (HVA) and dihydroxyphenyl acetic acid (DOPAC), thereby effectively improving insomnia. Through research on the effect of the acetyl dopamine dimer A on improving insomnia, the application obtains the basis of using the acetyl dopamine dimer A for improving insomnia, provides data support for research and development of the cicada slough as a medicine, and also provides a new medicinal source for improving insomnia.

The invention provides an ELISA reagent composition and kit for detecting brain-derived neurotrophic factors, and relates to the technical field of biological detection. The invention provides an ELISA (Enzyme-Linked Immunosorbent Assay) reagent composition for detecting brain-derived neurotrophic factors, the ELISA reagent composition is a sample diluent, and the sample diluent is composed of a buffer solution, bovine serum albumin, trehalose, polyethylene glycol 6000, propamidine dihydrochloride, glutathione and AEBSF. The ELISA reagent composition and the kit containing the ELISA reagent composition have good specificity and accuracy, and the coefficient of variation of a repetitive experiment is smaller than 10%, so that the kit has good repeatability and can be applied to detection of the content of BDNF in human serum.

To provide nucleic acids (including AAV expression cassettes), AAV vectors, and compositions for use in methods of treating and / or delaying the onset of diseases associated with mutations in mecp2 genes, such as Rett Syndrome.SOLUTION: Also provided herein are methods for treating a brain-derived neurotrophic factor (BDNF) - associated disease and / or delaying the onset of a brain-derived neurotrophic factor (BDNF) - associated disease. The present disclosure provides a nucleic acid comprising an adeno-associated virus (AAV) expression cassette, wherein the AAV expression cassette comprises, in a 5' to 3' direction, a 5' inverted terminal repeat (ITR), a synthetic activity-dependent promoter, a Rett syndrome-associated gene, and a 3' ITR.SELECTED DRAWING: None

The invention discloses a lactobacillus reuteri source extracellular vesicle for preventing and relieving senescence syndrome by relieving immune cell senescence, and belongs to the technical field of microorganisms and the technical field of medicines. The extracellular vesicle provided by the invention can improve learning, memory and cognitive abilities; the muscle strength capability is enhanced; the exercise coordination ability is improved; the motion balance capability is enhanced; the blood inflammatory factor level is obviously reduced, and the anti-inflammatory factor level is improved; the enzyme activity of the senescence-related enzyme SA-beta-Gal in the brain tissue is obviously reduced; the expression levels of brain-derived neurotrophic factors and neurotransmitters are obviously up-regulated; the collagen content and the collagen synthesis capability in skin tissues are obviously improved. The lactobacillus reuteri CCFM1471 source extracellular vesicles do not generate toxic and side effects in a host body, can be used for preparing functional foods and / or dietary supplements and related beauty products with the effects of preventing and relieving senescence syndromes, and have huge application prospects.

The present invention provides novel irisin peptides (e.g, irisin glycosylation mutants and biologically active fragments thereof). Also provided are methods for preventing or reducing degeneration of dopaminergic neurons and / or preventing or ameliorating at least one motor deficit in a subject in need thereof, such as in a subject with α-synucleinopathy, using the novel irisin peptides to modulate irisin-induced integrin signaling. The novel irisin peptides can also be used in methods for increasing expression of brain-derived neurotrophic factor (BDNF), and / or treating or preventing neurological diseases or disorders that would benefit from decreased neuronal cell death and / or increased neuronal survival in a subject. In addition, the novel irisin peptides may be used in methods for preventing or treating muscular atrophy or muscular dystrophy.

The present application belongs to the technical field of nutrient research, and particularly relates to a nutrient composition for promoting brain development and use thereof. The nutrient composition provided by the present application comprises two necessary components: i) lysophosphatidyl ethanolamine; and ii) docosahexaenoic acid; and the mass ratio of the lysophosphatidyl ethanolamine to the docosahexaenoic acid in the nutrient composition is 1:(10-2100). The combination of lysophosphatidyl ethanolamine and docosahexaenoic acid can effectively promote the overall growth and development of the body, especially the brain development, increase the expression levels of brain-derived neurotrophic factor and glial cell-derived neurotrophic factor in brain tissue, and effectively assist the improvement of cognitive ability.

The invention discloses a central obesity early warning method and system based on BDNF dynamic monitoring, and relates to the field of dynamic monitoring of brain-derived neurotrophic factors.The method comprises the steps that the weight, the body length, the body temperature and the food intake of an experimental subject are obtained, fasting blood glucose and blood fat are detected through caudal vein blood sampling, a standardized physiological index data set is formed, and the standard physiological index data set is stored in a database; the method comprises the following steps: carrying out anatomical sampling on hypothalamus tissues, scapular brown adipose and perirenal adipose, and carrying out Western Blot detection to obtain the BDNF expression quantity of the hypothalamus tissues, the BDNF expression quantity of the scapular brown adipose tissues and the BDNF expression quantity of the perirenal adipose tissues; and acquiring the BDNF concentration time sequence data of the hypothalamus extracellular fluid through the implanted microdialysis module. According to the method, dynamic continuous monitoring of hypothalamic BDNF secretion is achieved through the implanted microdialysis technology, the rhythm disorder degree is quantified by calculating the sample entropy value, the limitation of a traditional static detection method is broken through, and early metabolic regulation abnormity can be captured more sensitively.

This invention provides methods of detecting biomarkers in the biofluid of sepsis-associated encephalopathy (SAE) patients, including but not limited to glial fibrillary acidic protein (GFAP), ubiquitin C-terminal hydrolase LI, Tan protein, Neurofilament light chain (NF-L), myelin basic protein (MBP), secretogranin, Copeptin, total all-spectrin, all-spectrin breakdown products (SBDP, including SBDP145, SBDP150, SBDP120 all-spectrin N-terminal fragment or SBDP150N), neuron specific enolase (NSE), mature brain derived neurotrophic factor (BDNF), and full-length Pro-BDNF. These biomarker peptides are markers of axonal and blood brain barrier integrity which can be used to diagnose SAE and to assess and predict cognitive performance and outcomes in acute presentations of sepsis.

The present application provides a kind of nutritional composition in the application of the product for improving learning, memory and cognitive ability.The nutritional composition includes animal bifidobacterium lactis subsp.CP-9 and 3'-sialyllactose.Animal bifidobacterium lactis subsp.CP-9 and 3'-sialyllactose can synergistically enhance the memory retention ability of the body, reduce the degree of learning and memory errors, and up-regulate the expression of oligodendrocyte transcription factor 2 coding gene, myelin basic protein coding gene and brain-derived neurotrophic factor coding gene, realize the double regulation of myelin formation and neurotrophic in hippocampus region of brain, synergistically improve the neural plasticity of central nervous system through gut-brain axis pathway, and then double improve the learning, memory and cognitive function of the body from the behavior and molecular level.

The application belongs to the technical field of biological drugs, and particularly relates to a preparation method of genetically modified human bone marrow mesenchymal stem cells and application thereof in treating nervous system diseases, in particular, multiple sclerosis. The human bone marrow mesenchymal stem cells are double-modified by brain-derived neurotrophic factor (BDNF) and anti-S1PR5 nanobody, so that the activity of the human bone marrow mesenchymal stem cells is improved, the survival of neurons or oligodendrocytes is promoted, cell apoptosis is inhibited, and myelin regeneration is promoted, and the human bone marrow mesenchymal stem cells can be applied to nervous system diseases, in particular, multiple sclerosis.

The present disclosure relates to oral compositions that include at least two agents selected from: agents that increase the concentration of glutamate; agents that increase dopamine production; agents that increase the concentration of brain-derived neurotrophic factor (BDNF); NMDA and / or AMPA receptor modulators; and acetylcholinesterase inhibitors. In son embodiments, a composition as provided herein includes D-glutamine present in an amount of about 20% to about 30% w / w of the composition; ginkgolide B present in an amount of about 0.1% to about 0.4% w / w of the composition; phosphatidylserine present in an amount of about 65% to about 80% w / w of the composition; and ascorbic acid present in an amount of about 0.5% to about 2.5% w / w of the composition. Such compositions are useful for improving memory and / or focus.

The invention discloses a genetically engineered membrane-anchored neurotrophic factor, an exosome and a preparation method thereof, and relates to the technical field of biology. The invention provides a recombinant brain-derived neurotrophic factor protein. The amino acid sequence of the recombinant brain-derived neurotrophic factor protein is shown as SEQ ID NO: 1. The genetically engineered membrane anchored neurotrophic factor exosome provided by the invention comprises a recombinant BDNF, and the recombinant BDNF has a transmembrane structural domain, an extracellular structural domain and an exosome sorting domain, can be highly enriched on an exosome membrane, retains the physiological activity of the BDNF, and promotes nerve cell survival and synaptic formation.

The present invention relates to human proBDNF muteins and methods for recombinantly producing biologically active human brain-derived neurotrophic factor (BDNF).

The application discloses application of bupropion hydrochloride tablets (75mg) in preparation of a medicine for treating stroke, and belongs to the technical field of new purposes of medicines. The core verifies the efficacy and safety of the medicine of the specification through systematic animal tests, aims at the problems of post-stroke neural function defect, motor dysfunction and insufficient neural plasticity, adopts a line plug method to prepare a rat focal cerebral ischemia (MCAO) model, sets multiple control tests, and explores the dosing effect of an equivalent dose of the bupropion hydrochloride tablets (75mg). The test results show that the medicine can significantly reduce the neural function defect score of the model animals, improve the motor coordination ability and the limb usage rate, increase the content of brain-derived neurotrophic factor (BDNF) in the brain, promote the repair of neural plasticity, and is safer than a high-dose scheme and has no obvious adverse reactions. Through complete animal test data, the application proves the effectiveness and safety of the bupropion hydrochloride tablets (75mg) in treating stroke, provides solid test basis for clinical conversion and application of the bupropion hydrochloride tablets (75mg), and has important medical application value.

The application belongs to the field of medicine and relates to application of an isoflavone compound, isoformononetin (IFM), in preparation of a medicine or health care product for preventing and treating depression; in mouse hippocampal neuron cells (HT22) or mouse microglial cells (BV2), IFM can reduce neuroinflammation caused by corticosterone (CORT) or lipopolysaccharide (LPS) and increase the expression level of brain-derived neurotrophic factor (BDNF); in a chronic mild unpredictable stress mouse depression model, IFM can relieve depression-like behavior of the mouse and reduce the inflammation level of brain tissue, indicating that IFM has a good effect of relieving depression; IFM degrades PDE4D protein by directly combining with a PDE4D target protein. The isoflavone compound IFM has the advantages of outstanding effect and high safety and is expected to develop into an effective medicine for treating and preventing depression.

The present invention relates to a method for diagnosing or determining the risk of suffering from Alzheimer's disease in a subject, wherein the method comprises determining the level of at least the biomarkers Neurofilament light Chain (NfL), brain-derived neurotrophic factor (BDNF), and tumor growth factor beta 1 (TGF-beta 1) and in addition determining the level of one or more biomarkers selected from the group comprising interleukin 18 (IL-18), Monocyte chemotactic protein-1 (MCP-1), Insulin-like growth factor (IGF) and Vascular endothelial growth factor (VEGF) in a sample of bodily fluid of said subject, calculating a score from the determined biomarker levels, and comparing said score with a reference score, and wherein said subject is diagnosed with Alzheimer's disease, or said subject is determined as having a risk of suffering from Alzheimer's disease, if the score is above said reference score.

The invention provides a betahistine-containing nano-microsphere and a preparation method thereof. The betahistine-containing nano-microsphere comprises: a carrier composed of a polyacetic acid-glycolic acid copolymer; a hydrophilic core entrapped in the carrier, wherein the hydrophilic core comprises a brain-derived neurotrophic factor and hyaluronic acid; the hydrophobic shell layer is entrapped on the surface of the carrier, and the hydrophobic shell layer comprises betahistine or pharmaceutically acceptable salts / derivatives thereof. The betahistine and the neurotrophic factor with the vestibular hair cell protection / regeneration effect are jointly entrapped in the carrier, the dual effects of improving circulation and repairing functions are achieved, a space-time synergistic core-shell structure and intelligent response targeted penetration are creatively integrated, and the key barrier of double-effect drug co-delivery is successfully overcome.

The application relates to the field of food technology, and particularly provides application of a nutritional composition and food. The application provides application of a nutritional composition in preparation of a product for promoting brain development; the nutritional composition comprises whey protein powder, casein glycomacropeptide and sialic acid; the mass ratio of the whey protein powder, the casein glycomacropeptide and the sialic acid is (1-30):(1-3.5):1; in the whey protein powder, the content of protein is 60-80 wt%, the content of fat is 16-22 wt%, and the content of phospholipid is 6-10 wt%. Compared with the prior art, the nutritional composition has a synergistic effect on promoting brain development, can not only promote expression of sialic acidase in the brain, but also can promote expression of brain-derived neurotrophic factor.

The application relates to the technical field of biological medicine, and particularly discloses a bifunctional fusion protein and application thereof in treating retinal degenerative diseases. The fusion protein is named Beva-1L, which is formed by fusing an amino acid sequence of human brain-derived neurotrophic factor (BDNF) with a light chain of an anti-vascular endothelial growth factor (VEGF) antibody, bevacizumab. The fusion protein can simultaneously inhibit VEGF-mediated pathological angiogenesis and provide neurotrophic support, and is used for treating retinal degenerative diseases such as diseases simulated by an rd10 mouse model. Experiments show that the amplitude of a retinal electrogram (ERG) of the rd10 mouse can be significantly improved by injecting the Beva-1L, and the effect is equivalent to that of a positive drug. The application also relates to a coding gene, an expression vector, a host cell, a pharmaceutical composition of the fusion protein and application thereof. The fusion protein has a bifunctional synergistic effect, and provides a new treatment strategy for retinal degenerative diseases.

Described is a low voltage, pulsed electrical stimulation device for controlling expression of Brain-Derived Neurotrophic Factor (“BDNF”), a useful protein, by tissues. Also described are methods of enhancing expression of BDNF in cells, particularly a method of stimulating the expression and / or release of BDNF in a cell having a gene encoding BDNF, wherein the method includes applying a bioelectric signal of from about 10 Hz to about 100 Hz (e.g., 5 Hz, 10 Hz, 40 Hz, 100 Hz, or 110 Hz) to the cell (e.g., directly, indirectly, or wirelessly). Applications in the treatment of Alzheimer's disease, depression, schizophrenia, and post-traumatic stress disorder are also disclosed.

The application belongs to the technical field of immune detection, and discloses a kit for proBDNF and mature BDNF ratio detection based on structural dynamics orientation and a preparation method thereof. The kit comprises a solid carrier and a detection reagent, and is configured with three antibodies determined based on brain-derived neurotrophic factor full-length conformation dynamics analysis: a first capture antibody targeting an inherent disordered region (SEQ ID NO: 1) of a proBDNF propeptide region; a second capture antibody, which is a neoepitope specific antibody, specifically binds to an N terminal (SEQ ID NO: 2) exposed by mature BDNF enzyme cutting, and the binding is strictly dependent on a free alpha-amino group of the first histidine; and a universal detection antibody combined with a Loop 4 region (SEQ ID NO: 3) of a mature domain. The application solves the problems of spatial steric hindrance and cross reaction in traditional immune detection through a structural biology strategy, and realizes accurate differentiation and ratio quantification of proBDNF and mature BDNF.

The application belongs to the technical field of proteins, and relates to a peptide for promoting synthesis of brain-derived neurotrophic factor (BDNF) and a preparation method and application thereof. The amino acid sequence of the peptide for promoting synthesis of brain-derived neurotrophic factor BDNF is SGFSKHF. The main effect of the peptide is that the peptide can protect CORT (corticosterone) from damaging PC12 cells, can spontaneously bind to a TrkB receptor, the structure of a complex formed after the binding is more stable, helps to activate a BDNF-TrkB-CREB pathway signal transduction, and then promotes generation of BDNF, thereby helping to delay occurrence and development of neurodegenerative diseases.

Compositions and methods are presented that substantially increase levels of BDNF in blood, and even more pronouncedly exosomal BDNF levels. Suitable compositions include whole coffee fruit extracts and powders that are orally administered at relatively low dosages.

The present application relates to the technical field of biological medicine, and more particularly to the application of virus modified micro-gel electrospun scaffold in nerve injury by inducing in-situ reprogramming of fibroblasts. The present application provides a micro-gel electrospun scaffold which is modified with a polydopamine coating and grafted with a shPTB lentivirus vector; the matrix of the scaffold is prepared from brain-derived neurotrophic factor, poly-L-lactic acid and hyaluronic acid. The present application also provides a preparation method and use of the scaffold. Compared with conventional nerve injury biomaterial therapy, the micro-gel electrospun scaffold system can improve multiple characteristics such as a large number of inflammatory factors generated in the microenvironment after injury, lack of neurotrophic factors, and scar tissue proliferation.

The application provides an ELISA reagent composition and kit for detecting brain-derived neurotrophic factor, and relates to the technical field of biological detection. The application provides an ELISA reagent composition for detecting brain-derived neurotrophic factor, wherein the ELISA reagent composition is a sample diluent, and the sample diluent is composed of a buffer, bovine serum albumin, trehalose, polyethylene glycol 6000, propamocine dihydrochloride, glutathione and AEBSF. The ELISA reagent composition and the kit comprising the same have good specificity and accuracy, and the coefficient of variation of a repetitive experiment is less than 10%, which indicates that the kit has good repeatability and can be applied to detecting the content of BDNF in human serum.

This invention relates to the use of a nutritional composition. Specifically, it is used for non-therapeutic purposes to increase the expression of brain-derived neurotrophic factor (BDNF) and / or glial cell-derived neurotrophic factor (GNF). The nutritional composition comprises medium- to long-chain fatty acid triglycerides and docosahexaenoic acid (DHA) in a mass ratio of 2:1 to 600:1. The nutritional composition can synergistically increase the expression of BDNF and / or GNF. This nutritional composition can also improve brain development and promote neural and / or cognitive development.